Proinflammatory cytokines and signaling pathways in intestinal innate immune cells

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 681-701

  Sartor, R Balfour ^a   Hoentjen, Frank ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27644543662     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50039-5     Document Type: Chapter

References (191)

1. Abreu-Martin M.T., Vidrich A., Lynch D.H., Targan S.R. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Immunol. 1995, 155:4147-4154.
2. Akira S., Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 1992, 127:25-50.
3. Albright C., Tonkonogy S.L., Sartor R.B. Endogenous IL-10 inhibits APC stimulation of T lymphocyte responses to luminal bacteria. Gastroenterol. 2002, 122:A270. (Abstract).
4. Andus T., Daig R., Vogl D., Aschenbrenner E., Lock G., Hollerbach S., Kollinger M., Scholmerich J., Gross V. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor agonist genotype 2. Gut 1997, 41:651-657.
5. Andus T., Targan S.R., Deem R., Toyoda H. Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg. Immunol. 1993, 5:11-17.
6. Arizono N., Kasugai T., Yamada M., Okada M., Morimoto M., Tei H., Newlands G.F., Miller H.R., Kitamura Y. Infection of Nippostrongylus brasiliensis induces development of mucosal-type but not connective tissue-type mast cells in genetically mast cell-deficient Ws/Ws rats. Blood 1993, 81:2572-2578.
7. Arnott I.D., Drummond H.E., Ghosh S. Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig. Dis. Sci. 2001, 46:402-409.
8. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., Schutz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J.F., Lehr H.A., Autschbach F., Schurmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P.R., Rose-John S., Neurath M.F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. 2000, 6:583-588.
9. Barnes P.J. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001, 56:928-936.
10. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996, 334:1717-1725.
11. Berg D.J., Zhang J., Weinstock J.V., Ismail H.F., Earle K.A., Alila H., Pamkcu R., Moore S., Lynch R.G. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002, 123:1527-1542.
12. Black R.A., Doedens J.R., Mahimkar R., Johnson R., Guo L., Wallace A., Virca D., Eisenman J., Slack J., Castner B., Sunnarborg S.W., Lee D.C., Cowling R., Jin G., Charrier K., Peschon J.J., Paxton R. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem. Soc. Symp. 2003, 39-52.
13. Bocker U., Damiao A., Holt L., Han D.S., Jobin C., Panja A., Mayer L., Sartor R.B. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology 1998, 115:1426-1438.
14. Bonen D.K., Ogura Y., Nicolae D.L., Inohara N., Saab L., Tanabe T., Chen F.F., Foster S.J., Duerr R.H., Brant S.R., Cho J.H., Nunez G. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003, 124:140-146.
15. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., Williams C.B., Domizio P., Walker-Smith J.A., MacDonald T.T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106:1455-1466.
16. Brown K.A., Back S.J., Ruchelli E.D., Markowitz J.F., Mascarenhas M., Verma R., Piccoli D.A., Baldassano R.N. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am. J. Gastroenterol. 2002, 97:2603-2608.
17. Casini-Raggi V., Kam L., Chong Y.J., Fiocchi C., Pizarro T.T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 1995, 154:2434-2440.
18. Chamaillard M., Hashimoto M., Horie Y., Masumoto J., Qiu S., Saab L., Ogura Y., Kawasaki A., Fukase K., Kusumoto S., Valvano M.A., Foster S.J., Mak T.W., Nunez G., Inohara N. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 2003, 4:702-707.
19. Chikano S., Sawada K., Shimoyama T., Kashiwamura S.I., Sugihara A., Sekikawa K., Terada N., Nakanishi K., Okamura H. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 2000, 47:779-786.
20. Cohn S.M., Schloemann S., Tessner T., Seibert K., Stenson W.F. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 1997, 99:1367-1379.
21. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J.G., Dower S.K., Sims J.E., Mantovani A. Interleukin-1 type II receptor: a decoy target for Il-1 that is regulated by IL-4. Science 1993, 261:472-475.
22. Colombel J.F., Loftus E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., Zinsmeister A.R., Sandborn W.J. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterol. 2004, 126:19-31.
23. Cominelli F., Arseneau K.A., Pizarro T.T. Cytokines and inflammatory mediators. Kirsner's Inflammatory Bowel Diseases 2004, 179-198. WB Saunders, Baltimore. R.B. Sartor, W.J. Sandborn (Eds.).
24. Cominelli F., Nast C.C., Dinarello C.A., Gentilini P., Zipser R.D. Regulation of eicosanoid production in rabbit colon by interleukin-1. Gastroenterology 1989, 97:1400-1405.
25. Cominelli F., Nast C.C., Duchini A., Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992, 103:65-71.
26. Cominelli F., Nast C.C., Llerena R., Dinarello C.A., Zipser R.D. Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J. Clin. Invest. 1990, 85:582-586.
27. Cominelli F., Pizarro T.T. Interleukin-1 receptor antagonist: a "novel" acute phase protein with antiinflammatory activities. J. Clin. Invest. 1997, 99:2813.
28. Cong Y., Weaver C.T., Lazenby A., Elson C.O. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J. Immunol. 2000, 165:2173-2182.
29. Corazza N., Eichenberger S., Eugster H.P., Mueller C. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J. Exp. Med. 1999, 190:1479-1492.
30. Corbaz A., ten Hove T., Herren S., Graber P., Schwartsburd B., Belzer I., Harrison J., Plitz T., Kosco-Vilbois M.H., Kim S.H., Dinarello C.A., Novick D., Van Deventer S., Chvatchko Y. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J. Immunol. 2002, 168:3608-3616.
31. Craggs A., West S., Curtis A., Welfare M., Hudson M., Donaldson P., Mansfield J. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand. J. Gastroenterol. 2001, 36:1173-1178.
32. Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., Rennick D.M. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10 deficient mice. J. Immunol. 1998, 161:3143-3149.
33. de Baey A., Mende I., Baretton G., Greiner A., Hartl W.H., Baeuerle P.A., Diepolder H.M. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J. Immunol. 2003, 170:5089-5094.
34. Dieckgraefe B.K., Korzenik J.R. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002, 360:1478-1480.
35. Dinarello C.A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 2000, 343:732-734.
36. Dionne S., Laberge S., Deslandres C., Seidman E.G. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin. Exp. Immunol. 2003, 133:108-114.
37. Droemann D., Goldmann T., Branscheid D., Clark R., Dalhoff K., Zabel P., Vollmer E. Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem. Cell. Biol. 2003, 119:103-108.
38. Dwinell M.B., Lugering N., Eckmann L., Kagnoff M.F. Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology 2001, 120:49-59.
39. Eaton A.D., Xu D., Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 2003, 108:196-203.
40. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., Hanauer S.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999, 117:1271-1277.
41. El-Haj T., Poole S., Farthing M.J., Ballinger A.B. Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin. Brain Res. 2002, 927:1-7.
42. Evgenikos N., Bartolo D.C., Hamer-Hodges D.W., Ghosh S. Assessment of ileoanal pouch inflammation by interleukin 1 beta and interleukin 8 concentrations in the gut lumen. Dis. Colon. Rectum. 2002, 45:249-255.
43. Fuss I.J., Boirivant M., Lacy B., Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J. Immunol. 2002, 168:900-908.
44. Fuss I.J., Marth T., Neurath M.F., Pearlstein G.R., Jain A., Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999, 117:1078-1088.
45. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la, Matte C., Strong S.A., Fiocchi C., Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996, 157:1261-1270.
46. Girardin S.E., Boneca I.G., Carneiro L.A., Antignac A., Jehanno M., Viala J., Tedin K., Taha M.K., Labigne A., Zahringer U., Coyle A.J., DiStefano P.S., Bertin J., Sansonetti P.J., Philpott D.J. Nod1 detects a unique neuropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
47. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D.J., Sansonetti P.J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278:8869-8872.
48. Girardin S.E., Travassos L.H., Herve M., Blanot D., Boneca I.G., Philpott D.J., Sansonetti P.J., Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 2003, (in press).
49. Gross V., Andus T., Caesar I., Roth M., Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992, 102:514-519.
50. Hacker U.T., Gomolka M., Keller E., Eigler A., Folwaczny C., Fricke H., Albert E., Loeschke K., Endres S. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut 1997, 40:623-627.
51. Haller D., Holt L., Schwabe R.F., Sartor R.B., Jobin C. Transforming growth factor-β 1 inhibits non-pathogenic gramnegative bacteria-induced NF-κB recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J. Biol. Chem. 2003, 278:23851-23860.
52. Haller D., Russo M.P., Sartor R.B., Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J. Biol. Chem. 2002, 277:38168-38178.
53. Hans W., Scholmerich J., Gross V., Falk W. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur. Cytokine Netw. 2000, 11:67-74.
54. Herfarth H.H., Mohanty S.P., Rath H.C., Tonkonogy S., Sartor R.B. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996, 39:836-845.
55. Hisamatsu T., Suzuki M., Podolsky D.K. Interferongamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells. J. Biol. Chem. 2003, 278:32962-32968.
56. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W., et al. CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124:993-1000.
57. Hogan S.P., Mishra A., Brandt E.B., Royalty M.P., Pope S.M., Zimmermann N., Foster P.S., Rothenberg M.E. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat. Immunol. 2001, 2:353-360.
58. Hommes D., van den Blink B., Plasse T., Bartelsman J., Xu C., Macpherson B., Tytgat G., Peppelenbosch M.P., Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122:7-14.
59. Hommes D.W., Peppelenbosch M.P., van Deventer S.J. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003, 52:144-151.
60. Hsueh W., Caplan M.S., Qu X.W., Tan X.D., De Plaen I.G., Gonzalez-Crussi F. Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. Pediatr. Dev. Pathol. 2003, 6:6-23.
61. Hyams J.S., Fitzgerald J.E., Treem W.R., Wyzga N., Kreutzer D.L. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993, 104:1285-1292.
62. Isaacs K.L., Sartor R.B., Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992, 103:1587-1595.
63. Ishikura T., Kanai T., Uraushihara K., Iiyama R., Makita S., Totsuka T., Yamazaki M., Sawada T., Nakamura T., Miyata T., Kitahora T., Hibi T., Hoshino T., Watanabe M. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J. Gastroenterol. Hepatol. 2003, 18:960-969.
64. Ito H. IL-6 and Crohn's disease. Curr. Drug. Targets. Inflamm. Allergy 2003, 2:125-130.
65. Ito H., Hirotani T., Yamamoto M., Ogawa H., Kishimoto T. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J. Gastroenterol. 2002, 37:56-61.
66. Jobin C., Sartor R.B. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am. J. Physiol. Cell Physiol. 2000, 278:C451-C462.
67. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001, 15:43-58.
68. Jones S.A., Horiuchi S., Novick D., Yamamoto N., Fuller G.M. Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur. J. Immunol. 1998, 28:3514-3522.
69. Jones S.A., Novick D., Horiuchi S., Yamamoto N., Szalai A.J., Fuller G.M. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J. Exp. Med. 1999, 189:599-604.
70. Jostock T., Mullberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 2001, 268:160-167.
71. Jung H.C., Eckmann L., Yang S.K., Panja A., Fierer J., Morzycka-Wroblewska E., Kagnoff M.F. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J. Clin. Invest. 1995, 95:55-65.
72. Kagnoff M.F., Eckmann L. Epithelial cells as sensors for microbial infection. J. Clin. Invest. 1997, 100:6-10.
73. Kanai T., Watanabe M., Okazawa A., Sato T., Yamazaki M., Okamoto S., Ishii H., Totsuka T., Iiyama R., Okamoto R., Ikeda M., Kurimoto M., Takeda K., Akira S., Hibi T. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001, 121:875-888.
74. Kaplanski G., Marin V., Montero-Julian F., Mantovani A., Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003, 24:25-29.
75. Kelsall B.L., Strober W. Peyer's patch dendritic cells and the induction of mucosal immune responses. Res. Immunol. 1997, 148:490-498.
76. Kim S.C., Tonkonogy S.L., Sartor R.B. Role of endogenous IL-10 in downregulating proinflammatory cytokine expression. Gastroenterology 2001, 120:A183. [abstract].
77. Kim Y.M., Talanian R.V., Li J., Billiar T.R. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1 beta-converting enzyme). J. Immunol. 1998, 161:4122-4128.
78. Kitani A., Fuss I.J., Nakamura K., Schwartz O.M., Usui T., Strober W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intransal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med. 2000, 192:41-52.
79. Kobayashi K., Inohara N., Hernandez L.D., Galan J.E., Nunez G., Janeway C.A., Medzhitov R., Flavell R.A. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194-199.
80. Kobayashi K.S., Eynon E.E., Flavell R.A. Intracellular debugging. Nat. Immunol. 2003, 4:652-654.
81. Kobayashi M., Kweon M.N., Kuwata H., Schreiber R.D., Kiyono H., Takeda K., Akira S. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 2003, 111:1297-1308.
82. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro T., Kotlyarov A., Forster I., Flavell R., Gaestel M., Tsichlis P., Cominelli F., Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 2002, 196:1563-1574.
83. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
84. Kosiewicz M.M., Nast C.C., Krishnan A., Rivera-Nieves J., Moskaluk C.A., Matsumoto S., Kozaiwa K., Cominelli F. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J. Clin. Invest. 2001, 107:695-702.
85. Koss K., Satsangi J., Welsh K.I., Jewell D.P. Is interleukin-6 important in inflammatory bowel disease?. Genes Immun. 2000, 1:207-212.
86. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
87. Kunkel S.L., Chensue S.W., Phan S.H. Prostaglandins as endogenous mediators of interleukin 1 production. J. Immunol. 1986, 136:186-192.
88. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
89. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
90. MacGillivray M., Herrera-Abreu M.T., Chow C.W., Shek C., Wang Q., Vachon E., Feng G.S., Siminovitch K.A., McCulloch C.A., Downey G.P. The protein tyrosine phosphatase SHP-2 regulates interleukin-1-induced ERK activation in fibroblasts. J. Biol. Chem. 2003, 278:27190-27198.
91. Mackay F., Browning J.L., Lawton P., Shah S.A., Comiskey M., Bhan A.K., Mizoguchi E., Terhorst C., Simpson S.J. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998, 115:1464-1475.
92. Mackay F., Kalled S.L. TNF ligands and receptors in autoimmunity: an update. Curr. Opin. Immunol. 2002, 14:783-790.
93. Mahida Y.R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. 2000, 6:21-33.
94. Mannon P., Fuss I., Mayer L., Elson C.O., Sandborn W.J., Orlin B., Goodman N., Groden C., Hornung R., Sulfold J., Veldman G.M., Schwertschalg U., Strober W. Anti-interleukin-12 treats active Crohn's disease. Gastroenterol. 2004, 126:A22. (abstract).
95. Mansfield J.C., Holden H., Tarlow J.K., Di Giovine F.S., McDowell T.L., Wilson A.G., Holdsworth C.D., Duff G.W. Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994, 106:637-642.
96. McAlindon M.E., Hawkey C.J., Mahida Y.R. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998, 42:214-219.
97. McCall R.D., Haskill S., Zimmermann E.M., Lund P.K., Thompson R.C., Sartor R.B. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994, 106:960-972.
98. McGee D.W., Beagley K.W., Aicher W.K., McGhee J.R. Transforming growth factor-beta and IL-1 beta act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. J. Immunol. 1993, 151:970-978.
99. McLoughlin R.M., Witowski J., Robson R.L., Wilkinson T.S., Hurst S.M., Williams A.S., Williams J.D., Rose-John S., Jones S.A., Topley N. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest. 2003, 112:598-607.
100. Mifflin R.C., Saada J.I., Di Mari J.F., Adegboyega P.A., Valentich J.D., Powell D.W. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am. J. Physiol. Cell. Physiol. 2002, 282:C824-C834.
101. Mitsuyama K., Toyonaga A., Sasaki E., Ishida O., Ikeda H., Tsuruta O., Harada K., Tateishi H., Nishiyama T., Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995, 36:45-49.
102. Mizoguchi E., Mizoguchi A., Takedatsu H., Cario E., de Jong Y.P., Ooi C.J., Xavier R.J., Terhorst C., Podolsky D.K., Bhan A.K. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002, 122:134-144.
103. Mohan M.J., Seaton T., Mitchell J., Howe A., Blackburn K., Burkhart W., Moyer M., Patel I., Waitt G.M., Becherer J.D., Moss M.L., Milla M.E. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002, 41:9462-9469.
104. Monteleone G., MacDonald T.T., Wathen N.C., Pallone F., Pender S.L. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999, 117:1069-1077.
105. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., Luzza F., Fusco A., Pallone F. Bioactive IL-18 expression is up-regulated in Crohn's disease. J. Immunol. 1999, 163:143-147.
106. Morteau O., Morham S.G., Sellon R., Dieleman L.A., Langenbach R., Smithies O., Sartor R.B. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 2000, 105:469-478.
107. Mudter J., Neurath M.F. The role of signal transducers and activators of transcription in T inflammatory bowel diseases. Inflamm. Bowel. Dis. 2003, 9:332-337.
108. Mudter J., Wirtz S., Galle P.R., Neurath M.F. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology 2002, 70:170-176.
109. Murtaugh M.P., Foss D.L. Inflammatory cytokines and antigen presenting cell activation. Vet. Immunol. Immunopathol. 2002, 87:109-121.
110. Musch E., Andus T., Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment. Pharmacol. Ther. 2002, 16:1233-1239.
111. Nakamura S., Otani T., Ijiri Y., Motoda R., Kurimoto M., Orita K. IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 2000, 164:3330-3336.
112. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001, 12:53-72.
113. Neumann D., Lienenklaus S., Rosati O., Martin M.U. IL-1 beta-induced phosphorylation of PKB/Akt depends on the presence of IRAK-1. Eur. J. Immunol. 2002, 32:3689-3698.
114. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 1996, 183:2605-2616.
115. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995, 182:1281-1290.
116. Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyer zum Buschenfelde K.H., Strober W., Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 1997, 27:1743-1750.
117. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., Heinrich P.C., Muller-Newen G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170:3263-3272.
118. Nikolaus S., Rutgeerts P., Fedorak R., Steinhart A.H., Wild G.E., Theuer D., Mohrle J., Schreiber S. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003, 52:1286-1290.
119. Nilsen E.M., Johansen F.E., Jahnsen F.L., Lundin K.E., Scholz T., Brandtzaeg P., Haraldsen G. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 1998, 42:635-642.
120. Nitta M., Hirata I., Toshina K., Murano M., Maemura K., Hamamoto N., Sasaki S., Yamauchi H., Katsu K. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand. J. Immunol. 2002, 56:66-75.
121. Noguchi M., Hiwatashi N., Liu Z.X., Toyota T. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion 2001, 63(Suppl 1):32-36.
122. O'Neil D.A., Porter E.M., Elewaut D., Anderson G.M., Eckmann L., Ganz T., Kagnoff M.F. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol. 1999, 163:6718-6724.
123. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., Schroeder L., Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 2000, 97:13766-13771.
124. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 2000, 51:289-298.
125. Persson T., Monsef N., Andersson P., Bjartell A., Malm J., Calafat J., Egesten A. Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin. Exp. Allergy 2003, 33:531-537.
126. Pizarro T.T., Michie M.H., Bentz M., Woraratanadharm J., Smith M.F., Foley E., Moskaluk C.A., Bickston S.J., Cominelli F. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 1999, 162:6829-6835.
127. Pothoulakis C., LaMont J.T. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G178-G183.
128. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 1999, 277:C183-C201.
129. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999, 340:1398-1405.
130. Probert C.S., Hearing S.D., Schreiber S., Kuhbacher T., Ghosh S., Arnott I.D., Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998-1002.
131. Pucilowska J.B., Williams K.L., Lund P.K. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G653-G659.
132. Pullman W.E., Elsbury S., Kobayashi M., Hapel A.J., Doe W.F. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992, 102:529-537.
133. Puren A.J., Fantuzzi G., Gu Y., Su M.S., Dinarello C.A. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J. Clin. Invest. 1998, 101:711-721.
134. Rachmilewitz D., Katakara K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., Raz E. Toll-like receptor 9 signaling mediates the antiinflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
135. Rath H.C., Herfarth H.H., Ikeda J.S., Grenther W.B., Hamm T.E., Balish E., Taurog J.D., Hammer R.E., Wilson K.H., Sartor R.B. Normal luminal bacteria, especially Bacteroides species mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Invest. 1996, 98:945-953.
136. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 1993, 94:174-181.
137. Rennick D.M., Fort M.M., Davidson N.J. Studies with IL-10-/-mice: an overview. J. Leukocyte. Biol. 1997, 61:389-396.
138. Ricci S., Macchia G., Ruggiero P., Maggi T., Bossu P., Xu L., Medaglini D., Tagliabue A., Hammarstrom L., Pozzi G., Boraschi D. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 2003, 3:15.
139. Rogler G., Andus T., Aschenbrenner E., Vogl D., Falk W., Scholmerich J., Gross V. Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 1997, 9:893-899.
140. Rogler G., Gelbmann C.M., Vogl D., Brunner M., Scholmerich J., Falk W., Andus T., Brand K. Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. Scand. J. Gastroenterol. 2001, 36:389-398.
141. Rosenstiel P., Fantini M., Brautigam K., Kuhbacher T., Waetzig G.H., Seegert D., Schreiber S. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124:1001-1009.
142. Sandborn W.J. Strategies for targeting tumour necrosis factor in IBD. Best Pract. Res. Clin. Gastroenterol. 2003, 17:105-117.
143. Sandborn W.J., Feagan B.G., Hanauer S.B., Present D.H., Sutherland L.R., Kamm M.A., Wolf D.C., Baker J.P., Hawkey C., Archambault A., Bernstein C.N., Novak C., Health P.K., Targan S.R. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330-1338.
144. Sands B.E., Tremaine W.J., Sandborn W.J., Rutgeerts P.J., Hanauer S.B., Mayer L., Targan S.R., Podolsky D.K. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel. Dis. 2001, 7:83-88.
145. Saniabadi A.R., Hanai H., Takeuchi K., Umemura K., Nakashima M., Adachi T., Shima C., Bjarnason I., Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. 2003, 7:48-59.
146. Sartor R.B. Innate immunity in the pathogenesis and therapy of IBD. J. Gastroenterol. 2003, 38:43-47.
147. Sartor R.B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994, 106:533-539.
148. Schottelius A.J., Mayo M.W., Sartor R.B., Baldwin A.S.J. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem. 1999, 274:31868-31874.
149. Sellon R.K., Tonkonogy S., Schultz M., Dieleman L.A., Grenther W., Balish E., Rennick D.M., Sartor R.B. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 1998, 66:5224-5231.
150. Siegmund B. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem. Pharmacol. 2002, 64:1-8.
151. Siegmund B., Lehr H.A., Fantuzzi G., Dinarello C.A. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 2001, 98:13249-13254.
152. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K, Born T.L., Derry J.M., Viney J.L. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820.
153. Smith P.D., Smythies L.E., Mosteller-Barnum M., Sibley D.A., Russell M.W., Merger M., Sellers M.T., Orenstein J.M., Shimada T., Graham M.F., Kubagawa H. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol. 2001, 167:2651-2656.
154. Spahn T.W., Herbst H., Rennert P.D., Lugering N., Masser C., Kraft M., Fontana A., Weiner H.L., Domschke W., Kucharzik T. Induction of colitis in mice deficient of Peyer's patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches. Am. J. Pathol. 2002, 161:2273-2282.
155. Spencer D.M., Veldman G.M., Banerjee S., Willis J., Levine A.D. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002, 122:94-105.
156. Stagg A.J., Hart A.L., Knight S.C., Kamm M.A. The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut 2003, 52:1522-1529.
157. Stead R.H., Dixon M.F., Bramwell N.H., Riddell R.H., Bienenstock J. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989, 97:575-585.
158. Strober W., Fuss I.J. The regulation of mucosal homeostasis and its relation to inflammatory bowel diseases. Kirsner's Inflammatory Bowel Diseases 2004, 60-79. WB Saunders, Baltimore. R.B. Sartor, W.J. Sandborn (Eds.).
159. Strong S.A., Pizarro T.T., Klein J.S., Cominelli F., Fiocchi C. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterol 1998, 114:1244-1256.
160. Sumer N., Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 1995, 7:597-602.
161. Suzuki M., Hisamatsu T., Podolsky D.K. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect. Immun. 2003, 71:3503-3511.
162. Sylvester F.A., Wyzga N., Hyams J.S., Gronowicz G.A. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J. Bone Miner. Res. 2002, 17:695-702.
163. Takeda K., Takeuchi O., Akira S. Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res. 2002, 8:459-463.
164. Tapping R.I., Tobias P.S. Mycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signaling. J. Endotoxin Res. 2003, 9:264-268.
165. Targan S.R., Deem R.L., Shanahan F. Role of mucosal T-cell-generated cytokines in epithelial cell injury. Immunol. Res. 1991, 10:472-478.
166. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997, 337:1029-1035.
167. ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., Drillenburg P., van Deventer S.J., Chvatchko Y., Te Velde A.A. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001, 121:1372-1379.
168. Thierfelder W.E., van Deursen J.M., Yamamoto K., Tripp R.A., Sarawar S.R., Carson R.T., Sangster M.Y., Vignali D.A., Doherty P.C., Grosveld G.C., Ihle J.N. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996, 382:171-174.
169. Tilg H., Vogelsang H., Ludwiczek O., Lochs H., Kaser A., Colombel J.F., Ulmer H., Rutgeerts P., Kruger S., Cortot A., D'Haens G., Harrer M., Gasche C., Wrba F., Kuhn I., Reinisch W. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
170. Tsugawa K., Jones M.K., Akahoshi T., Moon W.S., Maehara Y., Hashizume M., Sarfeh I.J., Tarnawski A.S. Abnormal PTEN expression in portal hypertensive gastric mucosa: A key to impaired PI 3-kinase/Akt activation and delayed injury healing?. FASEB J. 2003, 17:2316-2318.
171. Tsukada Y., Nakamura T., Iimura M., Iizuka B.E., Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am. J. Gastroenterol. 2002, 97:2820-2828.
172. Tumanov A.V., Kuprash D.V., Nedospasov S.A. The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. Cytokine Growth Factor Rev. 2003, 14:275-288.
173. Vallance B.A., Blennerhassett P.A., Deng Y., Matthaei K.I., Young I.G., Collins S.M. IL-5 contributes to worm expulsion and muscle hypercontractility in a primary T. spiralis infection. Am. J. Physiol. 1998, 277:G400-G408.
174. Van den Brande J.M., Braat H., Van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., van Deventer S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
175. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., Hassard P.V., Papadakis K.A., Yang H., Zeldis J.B., Targan S.R. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999, 117:1278-1287.
176. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 2002, 168:5342-5351.
177. Watanabe N., Ikuta K., Okazaki K., Nakase H., Tabata Y., Matsuura M., Tamaki H., Kawanami C., Honjo T., Chiba T. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig. Dis. Sci. 2003, 48:408-414.
178. Watson J.M., Lofquist A.K., Rinehart C.A., Olsen J.C., Makarov S.S., Kaufman D.G., Haskill J.S. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1 beta. J. Immunol. 1995, 155:4467-4475.
179. Winsor G.L., Waterhouse C.C., MacLellan R.L., Stadnyk A.W. Interleukin-4 and IFN-gamma differentially stimulate macrophage chemoattractant protein-1 (MCP-1) and eotaxin production by intestinal epithelial cells. J. Interferon Cytokine. Res. 2000, 20:299-308.
180. Wirtz S., Becker C., Blumberg R.S., Galle P.R., Neurath M.F. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J. Immunol. 2002, 168:411-420.
181. Xia C.Q., Kao K.J. Suppression of interleukin-12 production through endogenously secreted interleukin-10 in activated dendritic cells: involvement of activation of extracellular signal-regulated protein kinase. Scand. J. Immunol. 2003, 58:23-32.
182. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101:311-320.
183. Xiong H., Zhu C., Li F., Hegazi R., He K., Babyatsky M., Bauer A.J., Plevy S.E. Inhibition of interleukin-12 p40 transcription and NFkB activation by nitric oxide in murine macrophages and dendritic cells. J. Biol. Chem. 2004, 279:10776-10783.
184. Yamada T., Deitch E., Specian R.D., Perry M.A., Sartor R.B., Grisham M.B. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993, 17:641-662.
185. Yamamoto M., Sato S., Hemmi H., Uematsu S., Hoshino K., Kaisho T., Takeuchi O., Takeda K., Akira S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 2003, 4:1144-1150.
186. Yamamoto M., Yoshizaki K., Kishimoto T., Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 2000, 164:4878-4882.
187. Yang S.K., Eckmann L., Panja A., Kagnoff M.F. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997, 113:1214-1223.
188. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., Hanada T., Takeda K., Akira S., Hoshijima M., Hirano T., Chien K.R., Yoshimura A. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 2003, 4:551-556.
189. Youngman K.R., Simon P.L., West G.A., Cominelli F., Rachmilewitz D., Klein J.S., Fiocchi C. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993, 104:749-758.
190. Zhang Z., Mahajan S., Zhang X., Stanley S.L. Tumor necrosis factor alpha is a key mediator of gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. Infect. Immun. 2003, 71:5355-5359.
191. Zhao X., Sato A., Dela Cruz C.S., Linehan M., Luegering A., Kucharzik T., Shirakawa A.K., Marquez G., Farber J.M., Williams I., Iwasaki A. CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer's patch CD11b+ dendritic cells. J. Immunol. 2003, 171:2797-2803.